
|Videos|April 14, 2023
ADT as the Backbone for Combination Treatments in Advanced Prostate Cancer
A focused discussion on how ADT is used as the backbone of prostate cancer therapy across different prostate cancer risk groups and according to metastatic and castration sensitivity status.
Advertisement
January 2023 AbbVie Inc. Company Confidential
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Initial prostate cancer presentation, family history linked to survival in mCRPC
2
Nicole L. Miller, MD, FACS, on persistent LUTS after BPH treatment
3
Datopotamab deruxtecan enters phase 3 trial in high-risk muscle-invasive urothelial cancer
4
AI system links surgical gestures with postoperative outcomes
5














